Immunological profile of mice immunized with a polyvalent virosome-based influenza vaccine

Virology Journal

Research

Wanessa Araújo Carvalho¹  Luciano Paulino da Silva²  Rejane Schaefer³  Ana Paula Bastos³  Francisco Noé Fonseca³  Danielle Gava³  Franciana Volpato Bellaver⁴  Gabrielly Bombassaro⁴  Vanessa Haach⁵  Lana Flavia Baron⁵  Mayara Simonelly⁶ 

[1] Embrapa Gado de Leite, Juiz de Fora-MG, Juiz de Fora, MG, Brazil;Embrapa Recursos Genéticos, Brasília, DF, Brazil;Embrapa Suínos e Aves, Concórdia, SC, Brazil;Instituto Federal Catarinense – Campus Concórdia, Concórdia, SC, Brazil;Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil;Universidade de Brasília, Brasília, DF, Brazil;

关键词: Vaccine;    Influenza a virus;    Vaccination;    Seroprotection;    Nanovaccine;   

DOI  :  10.1186/s12985-023-02158-0

 received in 2023-05-24, accepted in 2023-08-11,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundInfluenza A virus (IAV) causes respiratory disease in pigs and is a major concern for public health. Vaccination of pigs is the most successful measure to mitigate the impact of the disease in the herds. Influenza-based virosome is an effective immunomodulating carrier that replicates the natural antigen presentation pathway and has tolerability profile due to their purity and biocompatibility.MethodsThis study aimed to develop a polyvalent virosome influenza vaccine containing the hemagglutinin and neuraminidase proteins derived from the swine IAVs (swIAVs) H1N1, H1N2 and H3N2 subtypes, and to investigate its effectiveness in mice as a potential vaccine for swine. Mice were immunized with two vaccine doses (1 and 15 days), intramuscularly and intranasally. At 21 days and eight months later after the second vaccine dose, mice were euthanized. The humoral and cellular immune responses in mice vaccinated intranasally or intramuscularly with a polyvalent influenza virosomal vaccine were investigated.ResultsOnly intramuscular vaccination induced high hemagglutination inhibition (HI) titers. Seroconversion and seroprotection (> 4-fold rise in HI antibody titers, reaching a titer of ≥ 1:40) were achieved in 80% of mice (intramuscularly vaccinated group) at 21 days after booster immunization. Virus-neutralizing antibody titers against IAV were detected at 8 months after vaccination, indicating long-lasting immunity. Overall, mice immunized with the virosome displayed greater ability for B, effector-T and memory-T cells from the spleen to respond to H1N1, H1N2 and H3N2 antigens.ConclusionsAll findings showed an efficient immune response against IAVs in mice vaccinated with a polyvalent virosome-based influenza vaccine.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

40854_2023_507_Article_IEq17.gif

40517_2023_266_Article_IEq47.gif

40517_2023_266_Article_IEq44.gif

40517_2023_266_Article_IEq38.gif

Fig. 2